Clinical Trial Applications / CRO

Collaborating with researchers and pharmaceutical companies to harness the power of ElucidVivo

Unprecedented Insights from ElucidVivo Facilitate....

Risk-Based Clinical Trial Patient Inclusion/Exclusion

  • Accurately assess current plaque composition to determine if therapeutic would be appropriate based on parameters of therapeutic indications (e.g., exclude patients with little/no or too severe atherosclerosis, especially for immuno-oncology where plaque may rupture)

  • For disease types beyond cardiovascular (e.g., oncology), exclude patients at high risk of cardiovascular event

Expansion of Druggable Patient Population (2x-3x) For Approved Biologics

  • Measure statistically significant biological drug response 9+ months earlier than any other available technique, validating response for earlier treatment in broader patient population 

Development of Drugs For Early-Stage Disease Treatment

  • Capture statistically significant therapeutic response among patients with subclinical disease, enabling early treatment to slow and prevent progression towards interventional care

A Plausible Path to Market For Anti-Inflammatory Drugs to Treat CVD

  • Quantitative measures of CVD response to anti-inflammatories reveals systemic inflammation as a dominant mechanistic driver vs. circulating lipids - includes the first non-invasive measurements of cap thickness, quantity/proximity to LRNC to the lumen, and zinc homeostasis

Reduced Cost of Clinical Trials By Over 50%

  • Reduce the size of clinical trial patient population required to achieve clinical endpoint using quantitative inclusion/exclusion criteria based on MACE/stroke prediction diagnostic vs. non-specific patient suitability markers

Longitudinal Tracking of CVD Biomarkers and Drug Response

Study Example: 

Determine the efficacy of a drug in clinical trials or during patient care by tracking plaque progression or
regression over time

Longitudinal plaque regression of a patient in response to a therapeutic



1-Year Follow-Up

Lipid Rich Necrotic Core

Source: “Treatment of Psoriasis With Biologic Therapy Is Associated With Improvement of Coronary Artery Plaque Lipid-Rich Necrotic Core.” Choi et al, 2020, Circulation

Partner With Us

To learn more about how ElucidVivo can enhance your clinical development process, please contact Our Sales and Clinical teams would look forward to discussing your needs and objectives. 

Notable Partnerships: